

 Early Warning System

IFC-48629

Luminova



---

## Quick Facts

<b>Countries</b>	Guatemala
<b>Specific Location</b>	Guatemala City
<b>Financial Institutions</b>	International Finance Corporation (IFC)
<b>Status</b>	Proposed
<b>Bank Risk Rating</b>	B
<b>Borrower</b>	Luminova Pharma Alliance, Inc.
<b>Sectors</b>	Industry and Trade
<b>Investment Type(s)</b>	Loan
<b>Investment Amount (USD)</b>	\$ 50.00 million



---

## Project Description

According to the Bank's website, the project consists of a financing to Luminova Pharma Company to support the execution of its strategic plan including: (i) international expansion; and (ii) increased capacity and new products launch.

The Project responds to the growing need for affordable and high-quality pharmaceuticals in LAC



---

## Early Warning System Project Analysis

This is a category B project according to IFC's Policy on Environmental and Social Sustainability.



---

## Investment Description

- International Finance Corporation (IFC)

The proposed IFC investment is an up to US\$50 million corporate C Loan for IFC's own account to be committed in two phases of US\$25 million each.



---

### Private Actors Description

Luminova is one of the largest pharma companies based in Central America engaged in the development, manufacture, and commercialization of generic pharmaceuticals. With two manufacturing facilities in Guatemala and more than 950 employees, Luminova has capacity for solids, semisolids, liquids, and injectables in the main therapeutical units including acute care (antibiotics, self-care, nutrition, anemia, respiratory self-care), and chronic care (cardio, diabetes, CNS, dyslipidemias, venous system, urology).

Luminova is owned by Mr. Michael Erichsen, the second generation of the Erichsen family, who is also the Company's Executive President.”



---

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Luminova Pharma Alliance Inc.	Client	-

---



---

## Contact Information

Luminova Pharma Alliance

Humberto Gonzalez

CFO

+(502)-5017-8159

hugonzalez@luminovapg.com

Edificio AVIA Nivel 12 Oficina 1200, Zona 10, Guatemala, Guatemala, C.A.

www.luminovapg.com

## ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

## ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at [CAO@worldbankgroup.org](mailto:CAO@worldbankgroup.org) You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>





---

**Bank Documents**

- [Environmental & Social Review Summary \(ESRS\)](#)